In 1899, Bayer (BAYRY) patented acetylsalicylic acid – what we now call aspirin. This “miracle drug” then became the cornerstone of one of the most powerful pharmaceutical empires the world had ever seen. Unfortunately for Bayer, by 1917, they had to give up the patent as part of World War I reparations. Poof. Gone. That’s […]
Tag Archives: (LLY)
There is a predictable arc to every great pharmaceutical story. First comes disbelief, then euphoria, then inevitability, and finally punishment for having believed too much of your own press. Novo Nordisk (NVO) reached that final phase in 2025, not because semaglutide stopped working, but because investors forgot how brutally unforgiving this business becomes once expectations […]
Mad Hedge Biotech and Healthcare Letter December 30, 2025 Fiat Lux Featured Trade: (BIOTECH’S WATERLOO: THE STOCKS THAT CONQUERED AND THE ONES THAT DIDN’T) (IDXX), (CAH), (HCA), (COR), (MCK), (GILD), (JNJ), (LLY), (ISRG), (WBA), (MRK), (BMY), (MRNA), (BIIB), (ILMN)
Napoleon once said, “In victory, you deserve champagne. In defeat, you need it.” Healthcare investors popped both in 2025. While the sector at large looked like a casualty of macro shrapnel, a few names marched through the battlefield with earnings like artillery fire – and stock prices to match. The top-line view was grim: the […]
Mad Hedge Biotech and Healthcare Letter December 23, 2025 Fiat Lux Featured Trade: (CLIMBING THE CLIFF IN REVERSE) (REGN), (AMGN), (MRK), (BMY), (NVO), (LLY)
A few months ago, I found myself sipping flat champagne on a Gulfstream out of Aspen, locked in one of those altitude-fueled biotech postmortems. On my left: a hedge fund manager freshly out of his biotech positions after a bruising year. On my right: a dermatologist who moonlights as a GLP‑1 evangelist. Regeneron (REGN) came […]
Mad Hedge Biotech and Healthcare Letter November 4, 2025 Fiat Lux Featured Trade: (THE LONG VIEW) (REGN), (SNY), (NVO), (LLY)
Ah, Regeneron (REGN). Once the golden child of ophthalmology, now the grizzled veteran of biotech, hobbling through a few Eylea-induced aches and pains. But here’s the punchline: this old dog is learning some new tricks. And Wall Street is finally starting to notice. After a year in the earnings penalty box, Regeneron just delivered a […]
Mad Hedge Biotech and Healthcare Letter October 28, 2025 Fiat Lux Featured Trade: (PROOF THAT SOMETIMES THE OBVIOUS PLAY IS OBVIOUSLY RIGHT) (LLY), (NVO)
Did you know that pharmaceutical companies waste approximately 40% of their production capacity every single day? It’s been that way since the 1950s when most drug manufacturing processes were designed. A lot of people have no clue about this inefficiency, but it’s about to become the difference between winning and losing in the obesity drug […]